Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Get Rating) Director International S.C.A. Artal purchased 16,173,800 shares of the business’s stock in a transaction on Monday, August 1st. The stock was bought at an average cost of $2.50 per share, with a total value of $40,434,500.00. Following the purchase, the director now owns 48,433,261 shares in the company, valued at $121,083,152.50. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Lexicon Pharmaceuticals Stock Down 0.4 %
LXRX opened at $2.37 on Tuesday. Lexicon Pharmaceuticals, Inc. has a 12 month low of $1.31 and a 12 month high of $6.33. The company has a market cap of $354.54 million, a P/E ratio of -3.82 and a beta of 1.50. The company has a current ratio of 4.68, a quick ratio of 4.68 and a debt-to-equity ratio of 0.25. The business’s 50-day moving average price is $2.20 and its 200-day moving average price is $2.32.
Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Rating) last posted its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, meeting the consensus estimate of ($0.16). The business had revenue of $0.04 million for the quarter. Lexicon Pharmaceuticals had a negative return on equity of 75.21% and a negative net margin of 29,310.39%. During the same period in the previous year, the firm posted ($0.15) earnings per share. On average, equities analysts expect that Lexicon Pharmaceuticals, Inc. will post -0.51 EPS for the current year.
Hedge Funds Weigh In On Lexicon Pharmaceuticals
Wall Street Analyst Weigh In
Separately, Citigroup boosted their price target on shares of Lexicon Pharmaceuticals from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Friday, July 1st.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain.
- Get a free copy of the StockNews.com research report on Lexicon Pharmaceuticals (LXRX)
- MarketBeat Podcast: Find Investing Opportunities For The Rest of 2022
- Deep Value High Yield Newell Brands Is Ready To Bottom
- The Colgate-Palmolive Growth Outlook Brightens
- These Stocks Outperformed Last Time There Was A Recession
- Does Rivian’s Stock Still Have A Future?
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.